UCB UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About UCB (EBR: UCB)
›
UCB (EBR: UCB) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9,000 employees.
The shares were at 279.60 EUR on 20 November 2026, up 22.5% over 52 weeks. Its 52-week range is 197.45 EUR to 301.20 EUR: the price is 7.2% below the high and 41.6% above the low.
At a market capitalisation of 53.31B EUR, it trades at 24.7 times trailing earnings and 18.7 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 28% for UCB. It pays a dividend yielding 0.51% (it pays out 13% of its earnings), against a median of 1.39% among the dividend payers in that peer group.
UCB reports return on equity of 14.3%, an operating margin of 29.5% and revenue up 22.5% year over year.
Its debt exceeds its cash by 2.82B EUR, a debt-to-equity ratio of 0.21. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 298.63 EUR is 6.8% above the current price. The next earnings report is expected on 24 February 2027.